NEWMAN MARY 4
4 · Audentes Therapeutics, Inc. · Filed Apr 2, 2018
Insider Transaction Report
Form 4
NEWMAN MARY
SVP, Regulatory Affairs
Transactions
- Sale
Common Stock
2018-03-15$30.79/sh−5,524$170,085→ 0 total - Exercise/Conversion
Common Stock
2018-03-15$2.19/sh+5,524$12,098→ 5,524 total - Exercise/Conversion
Common Stock
2018-03-15$2.19/sh+400$876→ 400 total - Sale
Common Stock
2018-03-15$31.62/sh−400$12,647→ 0 total - Exercise/Conversion
Common Stock
2018-03-15$2.19/sh+4,076$8,926→ 4,076 total - Exercise/Conversion
Stock Option (right to buy)
2018-03-15−10,000→ 23,817 totalExercise: $2.19Exp: 2025-02-04→ Common Stock (10,000 underlying) - Sale
Common Stock
2018-03-15$29.66/sh−4,076$120,895→ 0 total
Footnotes (5)
- [F1]This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
- [F2]Represents the weighted average sale price. The lowest price at which shares were sold was $29.25 and the highest price at which shares were sold was $30.24. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes 2, 3 and 4 to this Form 4.
- [F3]Represents the weighted average sale price. The lowest price at which shares were sold was $30.27 and the highest price at which shares were sold was $31.20.
- [F4]Represents the weighted average sale price. The lowest price at which shares were sold was $31.50 and the highest price at which shares were sold was $31.66.
- [F5]The option vested as to 25% of the total shares on October 1, 2015, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on October 1, 2018, subject to the reporting person's provision of service to the issuer on each vesting date.